We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-9.64%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$585M
AUM Growth
-$73.1M
Cap. Flow
+$1.63M
Cap. Flow %
0.28%
Top 10 Hldgs %
31.26%
Holding
141
New
43
Increased
25
Reduced
14
Closed
51

Top Buys

Rank Stock Value
1
GRFS
Grifois
GRFS
+$10.6M
2
XENT
Intersect ENT, Inc
XENT
+$6.54M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.92M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.92M
5
ESTA icon
Establishment Labs
ESTA
+$5.5M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$10.1M
2
DHR icon
Danaher
DHR
+$7.15M
3
ARQL
Arqule Inc
ARQL
+$6.98M
4
GH icon
Guardant Health
GH
+$6.04M
5
ABBV icon
AbbVie
ABBV
+$5.82M

Sector Composition

Rank Sector Weight
1 Healthcare 39.74%
2 Industrials 1.15%
3 Consumer Staples 0.71%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRCE
126
Grace Therapeutics
GRCE
$44.6M
– –
-6,940
Closed -$380K
ITCI
127
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-300,000
Closed -$3.89M
CTLT
128
DELISTED
CATALENT, INC.
CTLT
– –
-80,000
Closed -$4.34M
AXNX
129
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-65,000
Closed -$2.66M
SILK
130
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-50,000
Closed -$2.42M
VAPO
131
DELISTED
Vapotherm, Inc. Common Stock
VAPO
– –
-17,500
Closed -$3.22M
SYNH
132
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-5,000
Closed -$255K
AMRS
133
DELISTED
Amyris Inc.
AMRS
– –
-247,668
Closed -$882K
APTO
134
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-333
Closed -$392K
CNCE
135
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-224,900
Closed -$2.7M
ABMD
136
PUT
DELISTED
Abiomed Inc
ABMD
– –
-30,000
Closed -$7.82M
QTNT
137
CALL
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-2,813
Closed -$1.05M
WMGI
138
DELISTED
Wright Medical Group Inc
WMGI
– –
-122,500
Closed -$2.92M
ARQL
139
CALL
DELISTED
Arqule Inc
ARQL
– –
-1,063,700
Closed -$11.7M
ARQL
140
DELISTED
Arqule Inc
ARQL
– –
-633,789
Closed -$6.98M
BEAT
141
PUT
DELISTED
BioTelemetry, Inc.
BEAT
– –
-50,000
Closed -$2.41M
2 3 4 5
6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2019 Portfolio in Review

As of Q3 2019, Pura Vida Investments held 141 positions worth $585M, down 11% from $658M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pura Vida Investments's Q3 2019 filing shows 43 new, 25 increased, 14 reduced and 51 closed positions. Its largest new stake was Grifois: 496,201 shares worth $9.94M. The largest sale was Boston Scientific, an estimated $10.1M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 45% a quarter earlier, followed by Industrials and Consumer Staples.

  • Pura Vida Investments's largest Q3 2019 buy was Grifois: 496,201 shares worth $9.94M.
  • Pura Vida Investments added most to Intersect ENT, Inc in Q3 2019, an estimated $6.54M increase.
  • Pura Vida Investments's biggest Q3 2019 reduction was Zimmer Biomet, cutting an estimated $5.66M.
  • Pura Vida Investments fully exited Boston Scientific in Q3 2019, selling an estimated $10.1M.
  • Pura Vida Investments's ten largest holdings make up 31% of its $585M portfolio in Q3 2019.
  • Pura Vida Investments opened 43 new positions and closed 51 in Q3 2019.
  • Pura Vida Investments's portfolio value fell 11% quarter-over-quarter to $585M.

Based on Pura Vida Investments's 13F filing for Q3 2019, filed 14 Nov 2019.